Parexel posts revenue increase in second quarter

Tuesday, January 31, 2012 02:23 PM

Boston-based CRO Parexel International posted a 9.5% increase in consolidated service revenue for the second quarter ended Dec. 31, 2011, to $333.2 million, from a year ago.

GAAP operating income for the quarter was $22.6 million, or 6.8% of consolidated service revenue (operating margin). GAAP net income totaled $12.9 million, or $0.21 per diluted share, compared with $16.8 million, or $0.28 per share, a year ago, a decrease of 23.1%. Excluding special items, adjusted operating income for the quarter was $23.8 million, or 7.1% operating margin, down 14% year-over-year.

Backlog at the end of December was approximately $3.74 billion, up 23.8% from a year ago.  The reported backlog included gross new business wins in the quarter of $622.2 million, cancellations of $121.7 million, a negative impact from foreign exchange rates of $29.7 million and a downward backlog adjustment of $3.8 million related to dispositions in the early phase business. The net book-to-bill ratio was 1.50 in the quarter.

“In the second quarter, we continued our positive momentum, demonstrating solid achievements in a number of key financial and operational areas,” said Josef H. von Rickenbach, Parexel’s chairman and CEO. “On a sequential basis, highlights included accelerated revenue growth for the company overall, an improved operating margin and earnings per share that were in line with our projections.  Our progress was broad-based, with each of our three reporting segments delivering higher gross margins on a sequential basis.  This was the result of improved operating leverage, further benefits of productivity and efficiency initiatives, and the impact of recent restructuring activities.”

Parexel issued forward-looking guidance for the third quarter of fiscal 2012 (ending March 31, 2012) and for fiscal 2012. It expects to report consolidated service revenue for the third quarter between $350 and $358 million, GAAP earnings per diluted share between $0.28 and $0.30 and adjusted earnings per diluted share between $0.30 and $0.32. For fiscal 2012, consolidated service revenue is expected between $1.360 and $1.375 billion, GAAP earnings per diluted share between $1.01 and $1.09, and adjusted earnings per diluted share between $1.09 and $1.17.  

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs